Skip to main content
NewslettersWatchlist

Antibe Therapeutics Inc(ATE-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.2600
Day High0.3500
Open:0.2600
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Monday (ATE)
AI-generated - The Globe and Mail
Antibe Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (ATE)
AI-generated - The Globe and Mail
Antibe Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (ATE)
AI-generated - The Globe and Mail
Antibe Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (ATE)
Baystreet
Stocks in play: Antibe Therapeutics Inc.
AI-generated - The Globe and Mail
Antibe Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (ATE)
Baystreet
Stocks in play: Antibe Therapeutics Inc.
AI-generated - The Globe and Mail
Antibe Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (ATE)
Baystreet
Stocks in play: Antibe Therapeutics Inc.
Baystreet
Stocks in play: Antibe Therapeutics Inc
AI-generated - The Globe and Mail
Antibe Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (ATE)
Baystreet
Stocks in play: Antibe Therapeutics Inc.
AI-generated - The Globe and Mail
Antibe Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (ATE)
Newswire.ca
Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite
The Globe and Mail
Antibe Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (ATE)
Business Wire
Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit
Business Wire
Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Baystreet
Stocks in play: Antibe Therapeutics Inc.
Business Wire
Antibe Provides April 2023 Corporate Update
Business Wire
Antibe Reports Q3 2023 Interim Financial and Operating Results
The Globe and Mail
Antibe Therapeutics: Top 25 Undervalued Dividend Stocks on TSX (ATE)
The Globe and Mail
Antibe Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (ATE)
The Globe and Mail
Antibe Therapeutics: Top 25 Undervalued Toronto Stock Exchange Stocks (ATE)
The Globe and Mail
Antibe Therapeutics: Top 10 Undervalued Nano Cap Stocks on TSX (ATE)
The Globe and Mail
Antibe Therapeutics: Stocks trading at Less Than Cash Value on TSX (ATE)
The Globe and Mail
Antibe Therapeutics: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (ATE)
The Globe and Mail
Antibe Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (ATE)
The Globe and Mail
Antibe Therapeutics: Stocks trading at Less Than Cash Value on TSX (ATE)
The Globe and Mail
Antibe Therapeutics: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (ATE)
The Globe and Mail
Antibe Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (ATE)
The Globe and Mail
Antibe Therapeutics: Stocks trading at Less Than Cash Value on TSX (ATE)
The Globe and Mail
Antibe Therapeutics: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (ATE)

Profile

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.